BNP Paribas Financial Markets Has $6.73 Million Stock Holdings in Avantor, Inc. (NYSE:AVTR)

BNP Paribas Financial Markets lifted its holdings in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 11.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 259,985 shares of the company's stock after buying an additional 27,626 shares during the period. BNP Paribas Financial Markets' holdings in Avantor were worth $6,726,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of AVTR. Sound Shore Management Inc. CT acquired a new stake in shares of Avantor in the 2nd quarter valued at approximately $76,412,000. Seven Eight Capital LP bought a new position in shares of Avantor in the 2nd quarter valued at about $642,000. New York State Teachers Retirement System acquired a new position in shares of Avantor during the 3rd quarter worth about $8,473,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Avantor by 35.1% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company's stock valued at $24,547,000 after purchasing an additional 300,579 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Avantor in the 2nd quarter valued at about $952,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AVTR has been the topic of several research analyst reports. Robert W. Baird dropped their price objective on Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Barclays cut their price target on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, October 25th. UBS Group decreased their price objective on shares of Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday, October 8th. Wells Fargo & Company cut their target price on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Monday, October 28th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.57.

Avantor Price Performance

Avantor stock traded down $0.01 during mid-day trading on Tuesday, reaching $21.09. 2,557,435 shares of the company were exchanged, compared to its average volume of 6,467,111. The company has a fifty day simple moving average of $23.28 and a 200-day simple moving average of $23.71. The firm has a market cap of $14.35 billion, a PE ratio of 45.85, a PEG ratio of 2.55 and a beta of 1.29. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00.

Insider Buying and Selling

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business's stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company's stock, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by company insiders.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.